| |
Relapse
|
NRM
|
Acute GVHD
|
Chronic GVHD
|
LFS
|
OS
|
|---|
| |
p value
|
HR (95 % CI)
|
p value
|
HR (95 % CI)
|
p value
|
OR (95 % CI)
|
p value
|
HR (95 % CI)
|
p value
|
HR (95 % CI)
|
p value
|
HR (95 % CI)
|
|---|
|
HLA 10/10 (ref)
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
|
|
HLA 9/10 versus 10/10
|
0.038
|
1.18 (1.01–1.38)
|
0.001
|
1.34 (1.13–1.58)
|
0.0001
|
1.47 (1.21–1.79)
|
0.418
|
1.07 (0.91–1.26)
|
0.0001
|
1.25 (1.11–1.40)
|
0.0001
|
1.27 (1.13–1.44)
|
|
HLA 8/10 versus 9/10
|
0.064
|
0.67 (0.43–1.02)
|
0.398
|
1.17 (0.81–1.68)
|
0.952
|
1.01 (0.63–1.62)
|
0.145
|
1.31 (0.91–1.88)
|
0.432
|
0.90 (0.68–1.18)
|
0.557
|
0.92 (0.69–1.22)
|
|
Age at SCT (10 years)
|
0.701
|
1.02 (0.91–1.15)
|
<10−5
|
1.41 (1.24–1.59)
|
0.465
|
1.05 (0.91–1.22)
|
0.501
|
1.04 (0.93–1.17)
|
0.0001
|
1.18 (1.09–1.29)
|
<10−5
|
1.25 (1.14–1.37)
|
|
Interval diag. to SCTa
|
0.007
|
0.96 (0.93–0.99)
|
0.636
|
1.01 (0.98–1.03)
|
0.306
|
0.98 (0.95–1.02)
|
0.833
|
1.00 (0.97–1.02)
|
0.108
|
0.98 (0.96–1.00)
|
0.122
|
0.98 (0.96–1.00)
|
|
Disease status at SCT
| | | | | | | | | | | | |
|
CR1 (ref)
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
| |
1.00
|
|
CR2 versus CR1
|
4.10−5
|
1.50 (1.24–1.82)
|
0.713
|
1.04 (0.85–1.28)
|
0.728
|
1.04 (0.82–1.32)
|
0.558
|
1.06 (0.88–1.28)
|
0.002
|
1.25 (1.09–1.44)
|
0.016
|
1.20 (1.03–1.39)
|
|
Act.dis. versus CR1
|
<10−5
|
2.06 (1.76–2.42)
|
0.001
|
1.35 (1.14–1.60)
|
0.004
|
1.34 (1.1–1.63)
|
0.019
|
1.22 (1.03–1.45)
|
<10−5
|
1.69 (1.51–1.90)
|
<10−5
|
1.63 (1.44–1.84)
|
|
Secondary AML
|
0.699
|
0.97 (0.83–1.13)
|
0.0004
|
1.32 (1.13–1.54)
|
0.418
|
1.08 (0.90–1.30)
|
0.196
|
1.11 (0.95–1.29)
|
0.029
|
1.13 (1.01–1.26)
|
0.021
|
1.14 (1.02–1.28)
|
|
Karnofsky ≥80 %
|
0.149
|
0.83 (0.64–1.07)
|
<10−5
|
0.55 (0.43–0.70)
|
0.838
|
0.97 (0.70–1.33)
|
0.318
|
0.86 (0.64–1.16)
|
10−5
|
0.68 (0.57–0.81)
|
<10−5
|
0.63 (0.58–0.76)
|
|
TBI
|
0.005
|
1.26 (1.07–1.48)
|
0.767
|
1.03 (0.85–1.24)
|
0.088
|
0.83 (0.67–1.03)
|
0.610
|
1.04 (0.88–1.24)
|
0.019
|
1.16 (1.02–1.30)
|
0.022
|
1.16 (1.02–1.32)
|
|
In vivo T cell depletion
|
0.483
|
1.07 (0.89–1.27)
|
0.253
|
0.90 (0.74–1.08)
|
<10−5
|
0.61 (0.49–0.75)
|
0.0001
|
0.72 (0.61–0.85)
|
0.790
|
0.98 (0.86–1.12)
|
0.72
|
0.98 (0.85–1.12)
|
|
Female D to male R
|
0.112
|
0.84 (0.68–1.04)
|
0.172
|
1.15 (0.94–1.42)
|
0.063
|
1.26 (0.99–1.61)
|
0.078
|
1.19 (0.98–1.45)
|
0.846
|
0.99 (0.85–1.14)
|
0.896
|
1.01 (0.87–1.18)
|
|
High CMV risk (R+/D−)
|
0.665
|
1.04 (0.87–1.24)
|
0.002
|
1.35 (1.11–1.65)
|
0.028
|
1.28 (1.03–1.60)
|
0.814
|
0.98 (0.82–1.17)
|
0.019
|
1.17 (1.03–1.33)
|
0.001
|
1.25 (1.09–1.43)
|
-
Act.dis. active disease, CR complete remission, D donor, D− donor, CMV serology, GVHD graft-versus-host-disease, LFS leukemia-free survival, NRM non relapse mortality, OS overall survival, PB Peripheral blood, Ref reference, R recipient, R+ positive recipient, CMV serology, SCT allogeneic stem cell transplantation, TBI total body irradiation
-
aAnalyzed per 6-month interval
